1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,006 | 0,008 | 20:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.04. | Aptamer Group PLC - Result of General Meeting | 1 | RNS | ||
| 31.03. | Aptamer Group PLC - Result of Retail Offer and Posting of Notice of GM | 1 | RNS | ||
| 26.03. | TRADING UPDATES: LPA to meet consensus; Aptamer raises GBP4.28 million | 3 | Alliance News | ||
| 26.03. | Aptamer Group PLC - Retail Offer to raise up to £0.5 million | 2 | RNS | ||
| 26.03. | Aptamer Group PLC - Results of Placing | - | RNS | ||
| 25.03. | Aptamer reports "meaningful" first-half progress alongside fundraise | 3 | Alliance News | ||
| 25.03. | Aptamer Group: Partnership cash helping to fund development | 1 | The Armchair Trader | ||
| 25.03. | Pharma-Verträge treiben Umsatz der Aptamer Group um 27 % | 1 | Investing.com Deutsch | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 25.03. | Aptamer Group reports 27% revenue increase in first half | 2 | Investing.com | ||
| 25.03. | Aptamer Group PLC - Interim Results and Notice of Investor Webinar | 3 | RNS | ||
| 25.03. | Aptamer Group PLC - Proposed Placing, Subscription and Retail Offer | 1 | RNS | ||
| 18.03. | Aptamer Group Introduces Targeted Radiopharmaceutical Program | 1 | Contract Pharma | ||
| 18.03. | Aptamer launches targets radiopharma development programme | 2 | Sharecast | ||
| 18.03. | Aptamer Group PLC - Launch of targeted radiopharmaceutical programme | - | RNS | ||
| 17.02. | Aptamer Group meldet wichtigen Meilenstein bei Projekt zur Pathogenerkennung | 2 | Investing.com Deutsch | ||
| 17.02. | Aptamer Group achieves technical milestone in pathogen detection project | 1 | Investing.com | ||
| 17.02. | Aptamer Group PLC - Technical Feasibility for Pathogen Detector | 1 | RNS | ||
| 11.02. | Aptamer Group PLC - Optimer Technology in Launched Library Prep Kit | - | RNS | ||
| 29.01. | Aptamer Group PLC - Contract wins and first cash licensing receipts | 1 | RNS | ||
| 07.01. | Aptamer Group PLC - Trading update - Media comment and speculation | - | RNS |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,020 | -21,09 % | Medigene: Zurückziehung - 18.11.2025 | ||
| CO.DON | 0,015 | +3,57 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp: Sirona Biochem to be delisted from NEX on April 21 | ||
| TME PHARMA | 0,066 | +11,73 % | TME Pharma NV: TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications | TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany, April 16, 2026, 08.00am CET - TME Pharma... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,093 | 0,00 % | Replenish Nutrients Expands Revolving Credit Facilities by $1.95 Million to Support Beiseker Scale-Up and Licensing Growth | ||
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,013 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2026 | Das Instrument B4A1 CH0208062627 MEIER TOBLER GRP AG NAM. EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2026 und ex Kapitalmassnahme am 09.04.2026 The instrument B4A1 CH0208062627 MEIER TOBLER... ► Artikel lesen | |
| BIOVAXYS TECHNOLOGY | 0,030 | 0,00 % | BioVaxys Technology Corp.: BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda ) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) | Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(Newsfile... ► Artikel lesen | |
| TELO GENOMICS | 0,030 | -9,09 % | Telo Genomics Corp (2): Telo Genomics debenture private placement | ||
| ALTERITY THERAPEUTICS | 0,006 | 0,00 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors | MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing... ► Artikel lesen | |
| MEDMIRA | 0,030 | 0,00 % | MedMira, Inc.: MedMira Reports Second Quarter Results FY2025 | HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026.Corporate updateIn Q2 FY2026, the Company... ► Artikel lesen | |
| GENETIC TECHNOLOGIES | 0,034 | -100,00 % | GENETIC TECHNOLOGIES LIMITED: Long Term Suspended Entities | ||
| BIOPHYTIS | 0,021 | -1,84 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.12.2025 | Das Instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM. EO -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 09.12.2025 und ex Kapitalmassnahme am 10.12.2025 The instrument 6XB3 FR001400OLP5 BIOPHYTIS NAM.... ► Artikel lesen | |
| ACTIVE BIOTECH | 0,006 | -4,92 % | Active Biotech AB: Active Biotech Year End Report 2025 | FOURTH QUARTER IN BRIEFActive Biotech announced a fully secured rights issue, subject to approval by an extraordinary general meeting, of approximately SEK 70 million before transaction costs (October... ► Artikel lesen |
APTAMER GROUP PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,015 (+300,00 %) liegt der Kurs bei 0,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAMER GROUP PLC finden Sie auf Wallstreet Online.